RNA (Ribonucleic Acid) room-temperature preservation stabilizer, RNA product as well as preparation method and application of RNA product

By functionalizing the interaction between polystyrene microspheres and RNA, a stable structure is formed, which solves the problems of high storage conditions and low biosafety in mRNA storage, and long-term stable storage of RNA at room temperature is achieved, reducing costs and improving security.

CN118910037AActive Publication Date: 2024-11-08BISHENG (BEIJING) BIOTECHNOLOGY CO LTD
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
CN202410942297.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-15
Publication Date
2024-11-08
Estimated Expiration
2044-07-15

AI Technical Summary

Technical Problem

There are problems in existing mRNA storage with high storage requirements, high storage costs and low biosecurity, especially in the increased energy consumption and safety problems caused by ultra-low temperature storage and protective agent use.

Method used

Provide a room temperature preservation stabilizer for RNA, using functionalized polystyrene microspheres as stabilizers, to form a specific three-dimensional structure by interacting with the functionalized groups of RNA, stabilize the RNA structure, and realize the room temperature of RNA through freeze-drying treatment. Long-term storage avoids the use of ultra-low temperature equipment and protective agents.

Benefits of technology

Long-term stable storage of RNA at room temperature is achieved, reducing storage costs, improving biosafety, and maintaining RNA integrity under different temperature conditions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118910037A_ABST
    Figure CN118910037A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of biology, and discloses an RNA (Ribonucleic Acid) room-temperature preservation stabilizer, an RNA product as well as a preparation method and application. The RNA room-temperature preservation stabilizer provided by the invention comprises the functionalized polystyrene microspheres, the RNA room-temperature preservation stabilizer has good adsorption capacity on RNA, and the functionalized groups on the RNA room-temperature preservation stabilizer can interact with groups in the RNA, so that RNA molecules are rotated, twisted, wound and folded to form a specific three-dimensional structure, the effect of stabilizing the RNA structure is achieved, and the RNA room-temperature preservation stabilizer can be used for storing RNA. The long-term stable storage of RNA at room temperature can be realized without introducing ultralow-temperature equipment and other protective reagents; the combination between the functionalized polystyrene microspheres and the RNA can be destroyed by adding water, the complete separation of the RNA and the stabilizer is realized, and the method has the advantages of low cost, simplicity in operation and high biological safety, and has a good application prospect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biotechnology, and in particular relates to an RNA room temperature storage stabilizer, an RNA product, and a preparation method and application thereof. Background Art

[0002] RNA is a long-chain molecule formed by condensation of ribonucleotides through phosphodiester bonds. It is widely present in biological cells, some viruses and viroids. Among them, mRNA can be responsible for transmitting genetic information and directly guiding protein synthesis during protein synthesis. It can be used in vaccines (infectious vaccines and tumor vaccines), protein replacement therapy, cell engineering and gene editing. By transferring mRNA to the cells of patients (or recipients), it can smoothly translate the specified protein and induce effective humoral and cellular immune responses to prevent diseases or change specific disease states. Compared with traditional drugs and vaccines, mRNA vaccines can be designed to encode any antigen according to the unique properties of the disease and regulate the expression of selected antigens, so that they can quickly respond to mutations in pathogenic microorganisms and provide more timely and reliable protection. However, the stability defects of the mRNA structure itself make it difficult to avoid degradation during storage and transportation, resulting in structural changes and reduced quality, which in turn affects the biological activity of mRNA.

[0003] At present, mRNA is generally stored by ultra-low temperature preservation, adding protective agents or a combination of the two. However, in ultra-low temperature preservation, mRNA is generally stored in an ultra-low temperature refrigerator at -80°C or even in liquid nitrogen to minimize its degradation rate, which places high demands on transportation and application scenarios, and will lead to problems such as increased energy consumption, increased transportation costs and safety; and the introduction of protective agents may reduce the biosafety of mRNA drugs or vaccines, which has great limitations. Summary of the invention

[0004] The first purpose of the present invention is to solve the problems of high storage conditions, high storage costs and low biosafety in the existing mRNA storage, and to obtain a simple, effective, economical and practical method with high biosafety for long-term stable storage and transportation of mRNA, and to provide an RNA room temperature storage stabilizer.

[0005] The second object of the present invention is to provide a method for preparing the above RNA room temperature storage stabilizer.

[0006] The third object of the present invention is to provide an RNA product.

[0007] The fourth object of the present invention is to provide a method for preparing an RNA product.

[0008] The fifth object of the present invention is to provide the application of the above RNA room temperature storage stabilizer and / or RNA product preparation method in the production of mRNA drugs and / or vaccines.

[0009] Specifically, the RNA room temperature storage stabilizer provided by the present invention includes functionalized polystyrene microspheres.

[0010] In some specific embodiments, the functionalized polystyrene microspheres are polystyrene microspheres modified with functional groups, and the functional groups are selected from one or more of C1-C20 chloroalkyl, chlorophenyl, C1-C20 hydroxyl-substituted alkyl, hydroxyl-substituted phenyl, C1-C20 carboxyl-substituted alkyl, carboxylic acid-substituted phenyl, C1-C20 amino-substituted alkyl, amino-substituted phenyl and nitrogen-containing heterocycles.

[0011] In some specific embodiments, the functionalized polystyrene microspheres are selected from one or more of chloromethyl-modified polystyrene microspheres, hydroxyl-modified polystyrene microspheres, carboxyl-modified polystyrene microspheres and nitrogen-containing five-membered heterocyclic-modified polystyrene microspheres.

[0012] In some specific embodiments, the average particle size of the functionalized polystyrene microspheres is 0.1 to 200 μm.

[0013] In some specific embodiments, the average particle size of the functionalized polystyrene microspheres is 1 to 2 μm.

[0014] The preparation method of the RNA room temperature storage stabilizer provided by the present invention comprises: S1, taking a polymerizable monomer, a functionalized modifier, an initiator and optional polystyrene particles to carry out a polymerization reaction to obtain the functionalized polystyrene microspheres; S2, taking the functionalized polystyrene microspheres to carry out a nuclease removal treatment to obtain the functionalized polystyrene microspheres.

[0015] In some specific embodiments, in step S1, the polymerizable monomer is selected from one or more of styrene, styrene propene and divinylbenzene.

[0016] In some specific embodiments, in step S1, the functional modifier is selected from one or more of chlorinated olefins, enols, unsaturated fatty acids and olefinated pyrrolidone.

[0017] In some specific embodiments, in step S1, the initiator is an azo initiator and / or a peroxide initiator.

[0018] In some specific embodiments, in step S1, the average particle size of the polystyrene particles is 0.01-1 μm.

[0019] In some specific embodiments, in step S1, the input mass ratio of the polymerization monomer, the functional modifier, the initiator and the optional polystyrene particles is (5-20):(0.1-20):(0.1-10):(0.001-20).

[0020] In some specific embodiments, in step S1, the polymerization reaction temperature is 70 to 90° C., and the time is 1 to 48 hours.

[0021] In some specific embodiments, the denuclease treatment specifically includes: taking the functionalized polystyrene microspheres and mixing them with RNase-free water, and then purifying them by centrifugal column to obtain the RNA room temperature storage stabilizer.

[0022] In some specific embodiments, the centrifugal speed of the centrifugal column purification is 5000-1000 rpm, and the time is 5-30 min.

[0023] The RNA product provided by the present invention comprises the above RNA room temperature storage stabilizer.

[0024] The preparation method of the RNA product provided by the present invention comprises: taking RNA and mixing it with an RNA room temperature storage stabilizer, and then freeze-drying it to obtain the RNA product.

[0025] In some specific embodiments, the input mass ratio of the RNA to the RNA room temperature storage stabilizer is 1:(10-1000).

[0026] In some specific embodiments, the freeze-drying process includes a pre-freezing stage, a primary drying stage and a secondary drying stage. The temperature of the pre-freezing stage is -60 to -50°C, and the time is 5 to 15 hours; the temperature of the primary drying stage is -45 to -40°C, the vacuum degree is not higher than 10Pa, and the time is 1 to 5 hours; the secondary drying stage includes alternating heating periods and constant temperature periods, the starting temperature of the secondary drying stage is -35 to -30°C, the final temperature is 20 to 25°C, the vacuum degree is not higher than 10Pa, the total time is 40 to 60 hours, and the heating rate of the heating period is 0.5 to 2°C / min, and the time is 25 to 40 minutes.

[0027] The present invention also provides the use of the above-mentioned RNA room temperature storage stabilizer, RNA product and / or RNA product preparation method in the production of mRNA drugs and / or vaccines.

[0028] Beneficial effects:

[0029] The invention provides an RNA room temperature storage stabilizer. The stabilizer comprises functionalized polystyrene microspheres. The functionalized polystyrene microspheres have good adsorption capacity for RNA. The functionalized groups on the functionalized polystyrene microspheres can interact with groups in RNA, so that RNA molecules rotate, twist, entangle and fold to form a specific three-dimensional structure, which plays a role in stabilizing the RNA structure. Long-term stable storage of RNA at room temperature can be achieved without introducing ultra-low temperature equipment and other protective reagents. Moreover, the addition of water can destroy the combination between the functionalized polystyrene microspheres and RNA, so as to achieve complete separation of RNA and the stabilizer. The stabilizer has the advantages of low cost, simple operation and high biosafety, and has good application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0030] Figure 1 This is the infrared spectrum of the PS-Cl microspheres prepared in Preparation Example 1 of the present invention;

[0031] Figure 2 This is the SEM image (200 μm) of the PS-Cl microspheres prepared in Preparation Example 1 of the present invention;

[0032] Figure 3 This is the infrared spectrum of the PS-OH microspheres prepared in Preparation Example 2 of the present invention;

[0033] Figure 4 This is the SEM image (5.0 μm) of the PS-OH microspheres prepared in Preparation Example 2 of the present invention;

[0034] Figure 5 This is the infrared spectrum of PS-COOH microspheres prepared in Preparation Example 3 of the present invention;

[0035] Figure 6 This is a SEM image (5.0 μm) of the PS-COOH microspheres prepared in Preparation Example 3 of the present invention;

[0036] Figure 7 This is the infrared spectrum of the PS-N microspheres prepared in Preparation Example 4 of the present invention;

[0037] Figure 8 This is the SEM image (5.0 μm) of the PS-N microspheres prepared in Preparation Example 4 of the present invention;

[0038] Fig. 9 This is a graph showing the experimental results of an electrophoresis test of an RNA product stored at 25° C. for 7 days in a test example of the present invention;

[0039] Fig.10 This is a graph showing the experimental results of an electrophoresis test of an RNA product stored at 25° C. for 21 days in a test example of the present invention;

[0040] Fig.11 This is a graph showing the experimental results of an electrophoresis test of an RNA product stored at 37° C. for 7 days in a test example of the present invention;

[0041] Fig.12 This is a graph showing the experimental results of an electrophoresis test of an RNA product stored at 37° C. for 21 days in a test example of the present invention;

[0042] Fig.13 This is a graph showing the experimental results of an electrophoresis test of an RNA product stored at 60° C. for 1 day in a test example of the present invention;

[0043] Fig.14 This is a graph showing the experimental results of an electrophoresis test of an RNA product stored at 60° C. for 5 days in a test example of the present invention;

[0044] Fig.15 This is a graph showing the experimental results of an electrophoresis test of an RNA product stored at 60° C. for 14 days in a test example of the present invention. DETAILED DESCRIPTION

[0045] The RNA room temperature storage stabilizer provided by the present invention specifically includes functionalized polystyrene microspheres. The functionalized polystyrene microspheres are specifically polystyrene microspheres modified with functionalized groups, and the functionalized groups specifically include C1-C20 chloroalkyl, C6-C20 chlorophenyl, C1-C20 hydroxyl substituted alkyl, C6-C20 hydroxyl substituted phenyl, C2-C20 carboxyl substituted alkyl, C7-C20 carboxylic acid substituted phenyl, C1-C20 amino substituted alkyl, C6-C20 amino substituted phenyl and C4-C20 nitrogen-containing heterocyclic ring or more. Among them, specific examples of the C1-C20 chloroalkyl include but are not limited to: -CH2Cl, -CH2CH(Cl)CH3 or -(CH2)5CH(Cl)CH3. Specific examples of the C6-C20 chlorophenyl include but are not limited to: 1-chloromethylphenyl, 2-chloromethylphenyl or 3-chloroethylphenyl. Specific examples of the C1-C20 hydroxy-substituted alkyl group include, but are not limited to: -CH2OH, -CH2CH2OH, -CH2CH(OH)CH3 or -(CH2)5CH(OH)CH3. Specific examples of the C6-C20 hydroxy-substituted phenyl group include, but are not limited to: 1-hydroxyphenyl, 2-hydroxyphenyl or 3-hydroxyphenyl. Specific examples of the C2-C20 carboxyl-substituted alkyl group include, but are not limited to: -CH2COOH, -(CH2) 12COOH or -(CH2)8CH(COOH)CH3. Specific examples of the C7-C20 carboxylic acid-substituted phenyl include, but are not limited to, 1-carboxyphenyl, 2-carboxyphenyl or 1-carboxyethylphenyl. Specific examples of the C1-C20 amino-substituted alkyl include, but are not limited to, -CH2NH3, -CH2NH3, -CH2CH2NH3, -CH2CH(NH3)CH3 or -(CH2)5CH(NH3)CH3. Specific examples of the C6-C20 amino-substituted phenyl include, but are not limited to, 1-aminophenyl, 2-aminophenyl or 1-aminomethylphenyl. The C4-C20 nitrogen-containing heterocycle is preferably a nitrogen-containing five-membered heterocycle, more preferably an N-ethyl-2-pyrrolidone group or a 1-(propyl)pyrrolidone-2-one group.

[0046] In the present invention, the functionalized polystyrene microspheres are preferably one or more of chloromethyl-modified polystyrene microspheres, hydroxyl-modified polystyrene microspheres, carboxyl-modified polystyrene microspheres and nitrogen-containing five-membered heterocyclic modified polystyrene microspheres. In some specific embodiments, the functionalized polystyrene microspheres are more preferably nitrogen-containing five-membered heterocyclic modified polystyrene microspheres. At this time, the nitrogen-containing five-membered heterocyclic modified polystyrene microspheres are rich in functionalized groups having a five-membered heterocyclic structure similar to ribose, which not only has a more ideal effect of stabilizing the RNA structure, but also can slow down the cleavage of RNA by ribonucleases, and have better protection and stabilization functions for RNA.

[0047] In the present invention, the average particle size of the functionalized polystyrene microspheres is preferably 0.1 to 200 μm, such as 0.1 μm, 0.5 μm, 1 μm, 5 μm, 10 μm, 15.6 μm, 25 μm, 50 μm, 78 μm, 90 μm, 99 μm, 100 μm or any value therebetween. In some specific embodiments, the average particle size of the functionalized polystyrene microspheres is more preferably 20 to 90 μm.

[0048] The preparation method of the RNA room temperature storage stabilizer provided by the present invention specifically comprises: S1, taking a polymerizable monomer, a functionalized modifier, an initiator and optional polystyrene particles to carry out a polymerization reaction to obtain the functionalized polystyrene microspheres; S2, taking the functionalized polystyrene microspheres to carry out a nuclease removal treatment to obtain the functionalized polystyrene microspheres.

[0049] In the present invention, the functionalized modifier in step S1 is a class of compounds that can react with polymerized monomers and then introduce functionalized groups into polystyrene microspheres during the polymerization of polystyrene. It can be selected according to the functionalized polystyrene microspheres to be obtained, and is not particularly limited. Specific examples include but are not limited to: one or more of chloroolefins, enols, unsaturated fatty acids and olefinated pyrrolidone. Among them, the chloroolefin can be specifically but not limited to one or more of 2-chlorostyrene, 3-chlorostyrene, chloromethylstyrene, 1-chloropropylene and 3-chloropropylene. The enol can be specifically but not limited to one or more of 2-propylene-1-ol, 3-butene-1-ol, 2-hydroxystyrene and 3-hydroxystyrene. Specific examples of the unsaturated fatty acid include but are not limited to one or more of oleic acid, linoleic acid, linolenic acid and arachidonic acid. The olefinated pyrrolidone can be specifically but not limited to N-vinyl-2-pyrrolidone and / or 1-(allyl)pyrrolidone-2-one.

[0050] In the present invention, the initiator in step S1 is a type of compound commonly used in existing polystyrene polymerization, which is limited to being able to decompose to generate free radicals and initiate polymerization reaction of polymerization monomers, and is not particularly limited thereto. Specific examples include but are not limited to: azo initiators and / or peroxide initiators. Among them, the azo initiator can be specifically but not limited to one or more of azobisisobutyronitrile, azobisisoheptanenitrile, dimethyl azobisisobutyrate and azoisobutylcyanamide. The peroxide initiator can be specifically but not limited to one or more of benzoyl peroxide, tert-butyl peroxy-2-ethylhexanoate and tert-butyl peroxybenzoate.

[0051] In the present invention, the addition of the polystyrene particles in step S1 is beneficial to the control of the shape and particle size of the microspheres, thereby obtaining functionalized polystyrene microspheres with better storage stability for RNA; the particle size of the polystyrene particles is preferably 0.01 to 1 μm, such as 0.01 μm, 0.03 μm, 0.05 μm, 0.07 μm, 0.1 μm, 0.25 μm, 0.4 μm, 0.6 μm, 0.8 μm, 1 μm or any value therebetween.

[0052] In the present invention, the input mass ratio of the polymerization monomer, functional modifier, initiator and optional polystyrene particles in step S1 is preferably (5-20):(0.1-20):(0.1-10):(0.001-20), such as 5:0.1:0.1:0.001, 5:13:7:19, 16:3:7:20, 20:0.1:0.1:19, 20:20:10:20 or any value therebetween.

[0053] In the present invention, the conditions of the polymerization reaction in step S1 include a temperature of preferably 70 to 90°C, such as 70°C, 71.5°C, 72°C, 73°C, 75°C, 78°C, 80°C, 81°C, 84°C, 88°C, 90°C or any value therebetween; and a time of preferably 1 to 48h, such as 1h, 4h, 10h, 12h, 15h, 18h, 24h, 30h, 38h, 48h or any value therebetween.

[0054] In the present invention, the denuclease treatment in step S2 specifically includes: taking the functionalized polystyrene microspheres and mixing them with RNase-free water, and then performing centrifugal column purification to obtain the RNA room temperature storage stabilizer.

[0055] In some specific embodiments, the conditions for centrifugal column purification include a centrifugal speed of preferably 5000-1000 rpm, such as 5000, 5100, 5500, 6000, 7000, 8000, 9000 or any value therebetween; and a time of preferably 5-30 min, such as 5 min, 7 min, 10 min, 13 min, 15 min, 20 min, 25 min, 27 min, 30 min or any value therebetween.

[0056] The RNA product provided by the present invention comprises the RNA room temperature storage stabilizer described above; by compounding the RNA room temperature storage stabilizer with RNA, the RNA product can be endowed with good room temperature storage stability.

[0057] The preparation method of the RNA product provided by the present invention specifically comprises: taking RNA and mixing it with an RNA room temperature storage stabilizer and then freeze-drying it to obtain the RNA product.

[0058] In the present invention, the input mass ratio of the RNA to the RNA room temperature storage stabilizer is preferably 1:(10-1000), such as 1:10, 1:50, 1:100, 1:125, 1:500, 1:1000 or any value therebetween.

[0059] In the present invention, the freeze-drying treatment may be carried out by the conventional methods and conditions used in the preparation of RNA products in the prior art, and such methods are not particularly limited as long as they can achieve dehydration and drying.

[0060] In the present invention, the freeze-drying treatment can also be a process designed by the inventors of the present invention after creative labor based on a deep understanding of the changes in the above-mentioned RNA room temperature storage stabilizer, RNA and water molecules during the treatment process, and the process specifically includes three stages: a pre-freezing stage, a primary drying stage and a secondary drying stage. Among them, the temperature of the pre-freezing stage is preferably -60 to -50°C, such as -60°C, -58°C, -54°C, -52°C, -51°C, -50°C or any value therebetween, and the time is preferably 5 to 15h, such as 5h, 5.8h, 6h, 7h, 9h, 10h, 12h, 15h or any value therebetween. The temperature of the primary drying stage is preferably -45 to -40°C, such as -45°C, -44.8°C, -43°C, -41.5°C, -40°C or any value therebetween; the vacuum degree is preferably not higher than 10Pa, more preferably 0 to 9Pa, such as 0Pa, 0.001Pa, 0.1Pa, 0.5Pa, 1Pa, 3Pa, 5Pa, 7Pa, 9Pa or any value therebetween; the time is preferably 1 to 5h, such as 1h, 1.3h, 1.5h, 2h, 2.5h, 3h, 4h, 5h or any value therebetween. The secondary drying stage comprises an alternating temperature rising period and a constant temperature period. The starting temperature of the secondary drying stage is preferably -35 to -30°C, such as -35°C, -34.8°C, -33°C, -31°C, -30°C or any value therebetween; the final temperature is preferably 20 to 25°C, such as 20°C, 21°C, 23°C, 24°C, 25°C or any value therebetween; the vacuum degree is preferably not higher than 10Pa, such as 0Pa, 0.001Pa, 0.3Pa, 1.5Pa, 3.2Pa, 5Pa, 9Pa or any value therebetween; the total time is preferably 40 to 60h, 40h, 41h, 43h, 45h, 50h, 51h, 56h, 59h, 60h or any value therebetween; the heating rate of the heating period is preferably 0.5-2°C / min, such as 0.5°C / min, 0.6°C / min, 0.8°C / min, 1°C / min, 1.5°C / min, 1.8°C / min, 2°C / min or any value therebetween; the time is preferably 25-40min, such as 25min, 25.6min, 28min, 30min, 33min, 35min, 37.6min, 38min, 40min or any value therebetween. At this time, the use of segmented freeze drying supplemented by intermittent heating can effectively reduce the damage to the RNA structure during the freeze drying process, and achieve a better binding effect between the functionalized polystyrene microspheres and the RNA, further improving the room temperature storage stability of the RNA product.

[0061] The present invention also provides the use of the above-mentioned RNA room temperature storage stabilizer, RNA product and / or the preparation method of the RNA product in the production of mRNA drugs and / or vaccines.

[0062] Embodiments of the present invention are described in detail below, and the examples of the embodiments are intended to be used to explain the present invention, but should not be construed as limiting the present invention. In the embodiments, if specific techniques or conditions are not specified, the techniques or conditions described in the literature in this area or the product specifications are used. If the manufacturer is not specified for reagents or instruments used, they are all conventional products that can be obtained commercially.

[0063] Synthesis example

[0064] This synthesis example is used to illustrate the preparation of a polystyrene microsphere, which specifically includes: accurately pipetting 9.8 mL of styrene, 15 mL of anhydrous ethanol and 125 mL of deionized water into a round-bottom flask, adding 652 mg of polyvinyl pyrrolidone (PVP K-30, weight average molecular weight of 58000) and 153.2 mg of benzoyl peroxide (BPO), vacuum degassing and rapidly stirring to an emulsion; then reacting in an oil bath at 73°C for 6 hours under a nitrogen atmosphere; cooling to room temperature after the reaction is completed, and the obtained emulsion is repeatedly washed 10 times with anhydrous ethanol, then continued to be washed 8 times with deionized water, and vacuum dried at 60°C for 48 hours to obtain polystyrene microspheres, which are recorded as PS microspheres.

[0065] Preparation Example 1

[0066] This preparation example is used to illustrate the preparation of a chloromethyl modified polystyrene microsphere, specifically comprising: accurately pipetting 17.6 mL of styrene, 2 mL of divinylbenzene, 5 mL of chloromethylstyrene and 250 mL of deionized water into a round-bottom flask, adding 2.0 g of polyvinyl alcohol (viscosity 6.0 mPa·s) and 500 mg of BPO, vacuum degassing and rapidly stirring to an emulsion; then reacting in an oil bath at 82° C. for 4 h under a nitrogen atmosphere; cooling to room temperature after the reaction is completed, the obtained emulsion is repeatedly washed 10 times with anhydrous ethanol, then continuously washed 8 times with deionized water, and vacuum dried at 60° C. for 48 h to obtain chloromethyl modified polystyrene microspheres, recorded as PS-Cl microspheres.

[0067] The SEM image and infrared spectrum of the PS-Cl microspheres prepared in this preparation example are shown in Figure 1 and 2 As shown in the figure, PS-Cl microspheres are spherical with smooth surface and diameter of 38-82 μm. -1 and 700-750cm -1 A strong absorption peak appeared nearby.

[0068] Preparation Example 2

[0069] This preparation example is used to illustrate the preparation of a hydroxyl-modified polystyrene microsphere, which specifically includes: accurately pipetting 9.0 mL of styrene, 50 μL of divinylbenzene, 1 mL of 3-butene-1-ol, 22 mL of anhydrous ethanol and 19.5 mL of deionized water into a round-bottom flask, adding 1.0 g of the PS microspheres provided in the synthesis example and 3.0 g of polyethylene glycol 4000, and ultrasonically dispersing for 30 minutes; then adding 0.182 g of ammonium persulfate and stirring thoroughly, vacuum degassing and rapidly stirring until an emulsion is in a state; then reacting in an oil bath at 70° C. for 12 hours under a nitrogen atmosphere; cooling to room temperature after the reaction is completed, the obtained emulsion is repeatedly washed 10 times with anhydrous ethanol, then continuously washed 8 times with deionized water, and vacuum dried at 60° C. for 48 hours to obtain hydroxyl-modified polystyrene microspheres, which are recorded as PS-OH microspheres.

[0070] The SEM image and infrared spectrum of the PS-OH microspheres prepared in this preparation example are shown in Figure 3 and 4 As shown in the figure, the PS-OH microspheres are spherical with certain surface defects, with a diameter of 2 to 3.5 μm and a wavelength of 3650-3600 cm -1 1500-1450cm -1 and 769-659cm -1 A strong absorption peak appeared nearby.

[0071] Preparation Example 3

[0072] This preparation example is used to illustrate the preparation of carboxyl-modified polystyrene microspheres, which specifically includes: accurately pipetting 20 mL of styrene, 0.2 mL of divinylbenzene, 2.0 mL of linoleic acid and 75 mL of anhydrous ethanol into a round-bottom flask, adding 1.5 g of PS microspheres provided in the synthesis example, 7.0 g of polyethylene glycol 4000 and 6.0 g of BPO, and ultrasonically dispersing for 30 minutes; vacuum degassing and rapid stirring to an emulsion; then reacting in an oil bath at 70°C for 10 hours under a nitrogen atmosphere; cooling to room temperature after the reaction is completed, and the obtained emulsion is repeatedly washed 10 times with anhydrous ethanol, then continued to be washed 8 times with deionized water, and vacuum dried at 60°C for 48 hours to obtain carboxyl-modified polystyrene microspheres, which are recorded as PS-COOH microspheres.

[0073] The SEM image and infrared spectrum of the PS-COOH microspheres prepared in this preparation example are shown in Figure 5 and 6 As shown in the figure, PS-COOH microspheres are spherical with smooth surface and a diameter of 2-3 μm. -1 、1720-1210cm -1 and 750-720cm -1 A strong absorption peak appeared nearby.

[0074] Preparation Example 4

[0075] This preparation example is used to illustrate the preparation of a nitrogen-containing five-membered heterocyclic ring modified polystyrene microsphere, specifically comprising: accurately pipetting 9.0 mL of styrene, 15 mL of anhydrous ethanol and 125 mL of deionized water into a round-bottom flask, adding 652 mg of polyvinyl pyrrolidone (PVP K-30, weight average molecular weight of 58000) and 122.5 mg of AIBN, vacuum degassing and rapidly stirring to an emulsion; then reacting in a 73°C oil bath under a nitrogen atmosphere for 15 hours, then adding 1 mL of N-vinyl-2-pyrrolidone and continuing to react for 3 hours; after the reaction is completed, cooling to room temperature, the obtained emulsion is repeatedly washed 10 times with anhydrous ethanol, then continuously washed 8 times with deionized water, and vacuum dried at 60°C for 48 hours to obtain nitrogen-containing five-membered heterocyclic ring modified polystyrene microspheres, recorded as PS-N microspheres.

[0076] The SEM images and infrared spectra of the PS-N microspheres prepared in this preparation example are shown in Figure 7 and 8 As shown in the figure, PS-N microspheres are spherical with smooth surface and diameter of 1-1.5 μm. -1 、1750-1370cm -1 and 750-650cm -1 A strong absorption peak appeared nearby.

[0077] Example 1

[0078] This example is used to illustrate a method for preparing an RNA product, and the storage method specifically includes:

[0079] S1. Pretreatment: (1) Take 3.5 mg of the PS-Cl microspheres provided in Preparation Example 1 and perform enzyme removal treatment by the centrifugal column method, repeat the washing 6 times, and vortex for 5 minutes each time; centrifuge at 7000 rpm for 30 seconds, add RNase-free water to the precipitate to a final volume of 200 μL, and obtain RNA room temperature storage stabilizer; (2) In a sterile enzyme-free operating table, add 10 μg of IVT RNA to 200 μL of RNA room temperature storage stabilizer to obtain an RNA sample, mix thoroughly, transfer to a vial, and half-stopper it.

[0080] S2. Freeze drying: Place the half-stoppered vial on the freeze drying chamber shelf of a four-ring vacuum freeze dryer (LGJ-S30 capping type) at room temperature, and perform freeze drying according to the procedure shown in Table 1 to obtain the RNA product.

[0081] S3. Transfer the vials containing RNA products to the transition room of the glove box, evacuate and replace with nitrogen, leave them overnight and move them to the operating room, and seal the vial caps with wax.

[0082] The IVT RNA used in step S1 of this embodiment is synthesized by using pUC19 plasmid DNA as a template, performing PCR reaction with primers of eGFP nucleotide sequence, and then in vitro transcription with T7 polymerase, and has a length of 850 nt.

[0083] Table 1.

[0084]

[0085] Example 2

[0086] The preparation method of the RNA product provided in this example is basically the same as that in Example 1, except that in step S1, the PS-OH microspheres provided in Preparation Example 2 of equal mass are used to replace the PS-Cl microspheres provided in Preparation Example 1, and the other conditions are the same to obtain the RNA product.

[0087] Example 3

[0088] The preparation method of the RNA product provided in this example is basically the same as that in Example 1, except that in step S1, the PS-COOH microspheres provided in Preparation Example 3 of equal mass are used to replace the PS-Cl microspheres provided in Preparation Example 1, and the other conditions are the same to obtain the RNA product.

[0089] Example 4

[0090] The preparation method of the RNA product provided in this example is basically the same as that in Example 1, except that in step S1, the PS-N microspheres provided in Preparation Example 4 of equal mass are used instead of the PS-Cl microspheres provided in Preparation Example 1, and the other conditions are the same to obtain the RNA product.

[0091] Example 5

[0092] The preparation method of the RNA product provided in this embodiment is basically the same as that in Example 1, except that in step S1, an epoxy-modified polystyrene microsphere (Zhiyi, brand name) of equal mass is used. PSEP) was used to replace the PS-Cl microspheres provided in Preparation Example 1, and the other conditions were the same to obtain RNA products.

[0093] Example 6

[0094] The preparation method of the RNA product provided in this embodiment is basically the same as that in Example 1, except that in step S1, the amount of IVT RNA added is 1 μg, and other conditions are the same to obtain an RNA product.

[0095] Example 7

[0096] The preparation method of the RNA product provided in this embodiment is basically the same as that in Example 1, except that in step S1, the amount of IVT RNA added is 200 μg, and other conditions are the same to obtain an RNA product.

[0097] Example 8

[0098] The preparation method of the RNA product provided in this embodiment is basically the same as that in Example 1, except that in step S2, the freeze-drying conditions are different, as shown in Table 2, to obtain the RNA product.

[0099] Table 2.

[0100]

[0101] Example 9

[0102] The preparation method of the RNA product provided in this embodiment is basically the same as that in Example 1, except that in step S2, the half-stoppered vial is directly placed at -70°C for freeze drying for 63 hours, and other conditions are the same to obtain the RNA product.

[0103] Comparative Example

[0104] This comparative example provides a method for preparing an RNA product, which specifically comprises:

[0105] S1. Pretreatment: Add 10 μg of IVT RNA to 200 μL of RNase-free water to obtain RNA sample. After thorough mixing, transfer to a vial and half-stopper it.

[0106] S2. Freeze drying: Place the half-stoppered vial on the freeze drying chamber shelf of a four-ring vacuum freeze dryer (LGJ-S30 capping type) at room temperature, and perform freeze drying according to the same procedure as in Example 1 (ie, Table 1) to obtain an RNA product.

[0107] S3. Transfer the vials containing RNA products to the transition room of the glove box, evacuate and replace with nitrogen, leave them overnight and move them to the operating room, and seal the vial caps with wax.

[0108] Test Case

[0109] This test example is used to illustrate the storage stability of the RNA products provided in the above embodiments and comparative examples. The RNA product was taken out after being stored at 25, 37 and 60°C for a period of time. In a sterile enzyme-free operating table, 100 μL of RNase-free water was taken to rehydrate the RNA product, shaken and mixed for 15 minutes, centrifuged at 7000 rpm for 4 minutes, and the supernatant was taken. The supernatant was filtered using a 0.22 μm RNase-free filter membrane. The RNA product with trehalose added as a protective agent was used as a positive quality control group. The preparation of the RNA product specifically includes: in a sterile enzyme-free operating table, 10 μg of IVT RNA was added to 200 μL of 1.72% (w:v) trehalose RNase-free aqueous solution to obtain an RNA sample, which was fully mixed and transferred to a vial and half-stoppered; the half-stoppered vial was placed on the freeze-drying chamber shelf of a four-ring vacuum freeze dryer (LGJ-S30 capping type) at room temperature, and freeze-dried according to the same procedure as in Example 1 (i.e., Table 1) to obtain an RNA product. And the detection was performed according to the following method:

[0110] (1) Capillary electrophoresis detection: 1 μL of the supernatant was taken and tested using an automatic capillary electrophoresis instrument (Agilent Fragment Analyzer 5200) to obtain the percentage of normal IVT RNA concentration to the total RNA concentration. The results are shown in Table 3.

[0111] Table 3.

[0112]

[0113] Note: -- indicates that normal RNA bands can no longer be detected and the RNA is completely degraded.

[0114] It can be seen from the test results that, compared with the comparative example, the RNA products provided by Examples 1 to 9 of the present invention and the positive quality control group can still maintain good RNA integrity after being stored at 37° C. for 21 days.

[0115] (2) Agarose gel electrophoresis detection: (i) Mix 0.5 g of agarose with 50 mL of 1×TAE solution and heat in a microwave oven until completely dissolved to obtain 1% agarose gel; after cooling for a few seconds, pour into an electrophoresis mold, cool into gel, remove the comb, put into a TAE electrophoresis tank, and pour in 1×TAE solution until the wells are filled with liquid and the solution covers the agarose gel;

[0116] (ii) Take 500 mg of sucrose, 500 μL of water and 5 μL of 10000×GeL Red to obtain Loading Dye sample buffer; take 3 μL of Ladder (TaKaRa, catalog number 3427A), add 15 μL of RNase-free water, and then add 2 μL of Loading Dye sample buffer to obtain Ladder electrophoresis sample solution;

[0117] (iii) Take 500 ng of the supernatant, 2 μL of Loading Dye, and add RNase-free water to a final volume of 20 μL to obtain the RNA electrophoresis loading solution;

[0118] (iv) Add the Ladder electrophoresis sample solution and RNA electrophoresis sample solution to the agarose gel well of the electrophoresis tank at once, cover the lid, and perform electrophoresis at 120V for 30 minutes; then transfer the gel to the Bio-Rad instrument and take a picture. The results are as follows: Figures 9 to 15 shown.

[0119] Depend on Fig. 9 and 10 It can be seen that after storage at 25°C for 7d and 21d, the bands of the comparative example showed slight downward diffusion, indicating that part of the RNA was degraded, while the bands of Examples 1 to 4 of the present invention were clearly visible and did not diffuse downward, indicating that the RNA room temperature storage stabilizer has a good protective and stabilizing effect on the freeze-drying of RNA and the storage process at 25°C.

[0120] Depend on Fig.11 and 12 It can be seen that after storage at 37°C for 7d and 21d, the bands of the comparative example showed slight downward diffusion, indicating that part of the RNA was degraded, while the bands of Examples 1 to 4 of the present invention were clearly visible and did not diffuse downward, indicating that the RNA room temperature storage stabilizer has a good protective and stabilizing effect on the freeze-drying of RNA and the storage process at 37°C.

[0121] Depend on Figures 13-15 It can be seen that after storage at 60°C for 1d and 5d, the bands of the comparative example showed slight and obvious downward diffusion, respectively, indicating that the RNA was degraded at 5d, while the bands of Examples 1 to 4 of the present invention did not undergo significant degradation; after storage at 60°C for 14d, the bands of the comparative example completely disappeared, while the bands of Examples 1 to 4 of the present invention were still clearly visible, with only partial degradation occurring, indicating that the RNA room temperature storage stabilizer has a good protective and stabilizing effect on the freeze-drying of RNA and the storage process at 60°C.

[0122] Although the embodiments of the present invention have been shown and described above, it is to be understood that the above embodiments are exemplary and are not to be construed as limitations on the present invention. A person skilled in the art may change, modify, replace and modify the above embodiments within the scope of the present invention without departing from the principles and intent of the present invention.

Claims

1. A RNA room temperature storage stabilizer, characterized in that The RNA room temperature storage stabilizer comprises functionalized polystyrene microspheres.

2. The RNA room temperature storage stabilizer according to claim 1, characterized in that The functionalized polystyrene microspheres are polystyrene microspheres modified with functional groups, wherein the functional groups are selected from one or more of C1-C20 chloroalkyl, C6-C20 chlorophenyl, C1-C20 hydroxyl-substituted alkyl, C6-C20 hydroxyl-substituted phenyl, C2-C20 carboxyl-substituted alkyl, C7-C20 carboxylic acid-substituted phenyl, C1-C20 amino-substituted alkyl, C6-C20 amino-substituted phenyl and C4-C20 nitrogen-containing heterocycle; Optionally, the functionalized polystyrene microspheres are selected from one or more of chloromethyl-modified polystyrene microspheres, hydroxyl-modified polystyrene microspheres, carboxyl-modified polystyrene microspheres and nitrogen-containing five-membered heterocyclic-modified polystyrene microspheres.

3. The RNA room temperature storage stabilizer according to claim 1, characterized in that The average particle size of the functionalized polystyrene microspheres is 0.1 to 200 μm; Optionally, the functionalized polystyrene microspheres have an average particle size of 1 to 2 μm.

4. The method for preparing the RNA room temperature storage stabilizer according to any one of claims 1 to 3, characterized in that: The preparation method comprises: S1, taking a polymerizable monomer, a functional modifier, an initiator and optional polystyrene particles to carry out a polymerization reaction to obtain the functionalized polystyrene microspheres; S2, taking the functionalized polystyrene microspheres to carry out a nuclease removal treatment to obtain the functionalized polystyrene microspheres.

5. The method for preparing the RNA room temperature storage stabilizer according to claim 4, characterized in that: In step S1, the polymerizable monomer is selected from one or more of styrene, styrene, propylene and divinylbenzene; Optionally, the functional modifier is selected from one or more of chlorinated olefins, enols, unsaturated fatty acids and olefinated pyrrolidones; Optionally, the initiator is an azo initiator and / or a peroxide initiator; Optionally, the average particle size of the polystyrene particles is 0.01 to 1 μm; Optionally, the input mass ratio of the polymerization monomer, functional modifier, initiator and optional polystyrene particles is (5-20):(0.1-20):(0.1-10):(0.001-20); Optionally, the polymerization reaction temperature is 70 to 90° C., and the time is 1 to 48 hours.

6. The method for preparing the RNA room temperature storage stabilizer according to claim 4, characterized in that: In step S2, the denuclease treatment specifically includes: taking the functionalized polystyrene microspheres and mixing them with RNase-free water and then performing centrifugal column purification to obtain the RNA room temperature storage stabilizer; Optionally, the centrifugal speed of the centrifugal column purification is 5000-1000 rpm, and the time is 5-30 min.

7. An RNA product, characterized in that: The invention comprises the RNA room temperature storage stabilizer according to any one of claims 1 to 3.

8. The method for preparing the RNA product according to claim 7, characterized in that: The preparation method comprises: taking RNA and mixing it with an RNA room temperature storage stabilizer, and then freeze-drying it to obtain the RNA product.

9. The method for preparing an RNA product according to claim 8, characterized in that: The input mass ratio of the RNA to the RNA room temperature storage stabilizer is 1:(10-1000); Optionally, the freeze-drying process includes a pre-freezing stage, a primary drying stage and a secondary drying stage, the temperature of the pre-freezing stage is -60 to -50°C, and the time is 5 to 15 hours; the temperature of the primary drying stage is -45 to -40°C, the vacuum degree is not higher than 10Pa, and the time is 1 to 5 hours; the secondary drying stage includes alternating heating periods and constant temperature periods, the starting temperature of the secondary drying stage is -35 to -30°C, the final temperature is 20 to 25°C, the vacuum degree is not higher than 10Pa, the total time is 40 to 60 hours, the heating rate of the heating period is 0.5 to 2°C / min, and the time is 25 to 40 minutes.

10. Use of the RNA room temperature storage stabilizer according to any one of claims 1 to 3, the RNA product according to claim 7, and / or the preparation method of the RNA product according to claim 8 or 9 in the production of mRNA drugs and / or vaccines.

Citation Information

Patent Citations

  • Nitrogen heterocyclic ring compound modified magnetic polystyrene microsphere, preparation method and application thereof

    CN104353435A

  • Preparation method for polystyrene (PS) microsphere used for nucleic acid amplification in genome sequencing

    CN104844742A

  • Polystyrene microsphere modification method

    CN108102020A

  • Preparation method of monodisperse magnetic polystyrene microspheres, microspheres and application thereof

    CN113278194A

  • Carboxylated quantum dot coded fluorescent microspheres, preparation method and application thereof

    CN113648942A